Acquiring the right products
for development
Biopharmaceutical companies are increasingly relying on product licensing and acquisition to build their product pipelines quickly and cost-efficiently. However, no company can afford to license a product only to discover that it has safety, efficacy, regulatory, or marketing issues that will reduce its value. To ensure that they make the right licensing decisions, many of these companies are turning to strategic partners with specialized expertise in early-stage product development to help them identify the most promising therapies and carry out additional testing and analysis before the products move forward into costly Phase III trials.
A strategic partner with experience in all stages of product development can also help speed the transition of new products into the later stages of development and accelerate time to market. By adapting this new paradigm of strategic partnerships for product acquisition and development, biopharmaceutical companies can maximize their resources, reduce overhead costs, and focus their resources on the products with the best chances for regulatory approval and marketplace success.
PAREXEL has the right early-phase experience to help you make informed licensing decisions and efficiently move your new product forward to reach the market as quickly as possible. Our global capabilities to support your in-licensing programs include:
- Due diligence and gap analyses
- Market and pricing/reimbursement analyses
- Clinical research cost analysis and planning
- Clinical development consulting
- Complete early-phase development programs
- Comprehensive Phase III/IV trial services
- Extensive site, patient, and investigator recruitment resources for every trial phase
- Advanced eClinical technologies, including EDC, CTMS, IVRS/IWRS, and medical imaging
- Risk management and pharmacovigilance programs
- GxP compliance auditing
- Strategic reimbursement planning
- Global regulatory consulting, preparation, and submissions